Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib and TAS-102 in Chemotherapy-Resistant RAS-Mutated Metastatic Colorectal Cancer
NCT03317119Phase 1Completed
- Sponsor
- City of Hope
- Start
- Apr 2018
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trametinib in metastatic colorectal cancer (mCRC), sponsored by City of Hope. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Apr 2018; status: completed.
02
Drugs
trametinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03317119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03317119.